Zacks Investment Research downgraded shares of Iterum Therapeutics (NASDAQ:ITRM) from a hold rating to a sell rating in a research note issued to investors on Wednesday.

According to Zacks, “Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company’s product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland. “

A number of other research firms have also weighed in on ITRM. Needham & Company LLC initiated coverage on shares of Iterum Therapeutics in a report on Tuesday, June 19th. They issued a buy rating and a $20.00 target price on the stock. Leerink Swann initiated coverage on shares of Iterum Therapeutics in a report on Tuesday, June 19th. They issued an outperform rating and a $18.00 target price on the stock. Guggenheim initiated coverage on shares of Iterum Therapeutics in a report on Tuesday, June 19th. They issued a buy rating and a $21.00 target price on the stock. Finally, Royal Bank of Canada assumed coverage on shares of Iterum Therapeutics in a report on Tuesday, June 19th. They issued an outperform rating and a $24.00 target price on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Iterum Therapeutics has an average rating of Buy and a consensus target price of $20.75.

Shares of ITRM traded down $0.16 on Wednesday, reaching $6.33. The company’s stock had a trading volume of 6,436 shares, compared to its average volume of 22,993. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.53 and a current ratio of 11.53. Iterum Therapeutics has a twelve month low of $5.84 and a twelve month high of $13.00.

Iterum Therapeutics (NASDAQ:ITRM) last posted its earnings results on Tuesday, August 14th. The company reported ($2.22) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.44) by ($0.78). The company had revenue of $0.19 million for the quarter. As a group, research analysts predict that Iterum Therapeutics will post -11.3 EPS for the current year.

A number of large investors have recently bought and sold shares of the business. Glen Harbor Capital Management LLC purchased a new stake in Iterum Therapeutics in the 2nd quarter valued at about $318,000. Dean Capital Investments Management LLC purchased a new stake in Iterum Therapeutics in the 2nd quarter valued at about $406,000. Tyers Asset Management LLC purchased a new stake in Iterum Therapeutics in the 2nd quarter valued at about $437,000. Flinton Capital Management LLC purchased a new stake in Iterum Therapeutics in the 2nd quarter valued at about $556,000. Finally, Neuburgh Advisers LLC purchased a new stake in Iterum Therapeutics in the 2nd quarter valued at about $675,000. Hedge funds and other institutional investors own 47.63% of the company’s stock.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

See Also: Stop Order

Get a free copy of the Zacks research report on Iterum Therapeutics (ITRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.